Bone Biologics Corp

Bone Biologics Corporation is a medical device company focused on bone regeneration solutions for spinal fusion procedures. The company's core technology is NELL-1, a recombinant human protein that provides targeted control over bone regeneration. Its lead product is NELL-1/DBM, a fusion device combining the recombinant protein with demineralized bone matrix for use in lumbar spinal fusion applications. The company holds a license agreement with UCLA Technology Development Group for developing and commercializing NELL-1 in spinal fusion indications.

The NELL-1 platform has potential applications across multiple surgical specialties including spine surgery, orthopedic surgery, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company primarily serves spine surgeons and patients requiring treatment for skeletal bone defects or spine-related bone conditions.

Bone Biologics operates as a small-scale organization with two full-time employees and is headquartered in Burlington, Massachusetts. The company was incorporated in Delaware and is listed on Nasdaq. Founded in 2004, the company remains in the development and commercialization phase of its lead spinal fusion device.